Challenges associated with the integration of immuno-oncology agents in clinical practice by Patrice Lazure, Aparna R. Parikh, Neal E. Ready, Marianne J. Davies, Sophie Péloquin, Jeffrey M. Caterino, Robert Lewandowski, Alexander J. Lazar, Suzanne Murray

Get full text

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial by Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD

Get full text

629-D The anti-tumor activity of IFNβ and membrane-stable CD40L expressing oncolytic virus MEM-288 in NSCLC patients is associated with modulation of the tumor microenvironment and... by Hong Zheng, Uzma Khan, Xiaofei Wang, Xiaoqing Yu, Georgia M Beasley, James Ronald, Jhanelle E Gray, Scott J Antonia, Steven Wolf, Neal E Ready, Bruna Pellini, Andreas N Saltos, Christy Arrowood, Ghassan El-Haddad, Tawee Tanvetyanon, Luiziane Guerra-Guevara, Lin Gu, Dana Foresman, Mark J Cantwell, Amer A Beg

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817 by Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo

Get full text